



Marine Antibiotics 2022

Guest Editor:

Dr. Yannick Fleury

Laboratoire de Biotechnologie et
Chimie Marine, Université de
Brest, Université de Bretagne
Sud, CNRS, LBCM, EMR 6076,
Quimper, France

Deadline for manuscript
submissions:

closed (29 July 2022)

Message from the Guest Editor

Nowadays, antimicrobial resistance (AMR) is expected to be one of the leading causes of death in the world in 2050 and, therefore, is considered as one of the most serious threats to global public health. It is clear that the renewal of the therapeutic arsenal is a major priority, if only to treat patients. However, despite considerable international efforts to tackle AMR, only 11 new antibiotics have been approved since July 2017. With the rate of success being very low, the antibiotic discovery has to be reinvigorated. The marine biodiversity is still an under-explored reservoir of bioactive compounds and it must play its full role in the race against time to design potent and effective drugs to tackle AMR.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
X@Marine_Drugs